Keith Gottesdiener
Chief Executive Officer chez PRIME MEDICINE, INC.
Fortune : 30 M $ au 31/03/2024
Profil
From October 2011 until March 2020, Dr. Gottesdiener served as the CEO of Rhythm Pharmaceuticals (RYTM).
Dr. Gottesdiener joined Rhythm after 16 years at Merck Research Laboratories, where he held positions of increasing responsibility, including leading Merck’s late clinical development organization from 2006 to 2011 and leading Merck’s early clinical development from 2001 through early 2006.
Dr. Gottesdiener oversaw the development of Merck’s infectious diseases and vaccine products through pivotal trials, registration, and life cycle management, including GardasilTM (HPV Vaccine), RotateqTM (rotavirus vaccine), ZostavaxTM (zoster vaccine) and IsentressTM (HIV integrase inhibitor), among others.
Dr. Gottesdiener received his B.A.
from Harvard College and his M.D.
from the University of Pennsylvania.
He completed his residency and fellowship at the Brigham and Women’s Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children’s Hospital programs.
After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory
of Dr. Jack Strominger at Dana Farber Cancer Institute working on the molecular immunology of the T-cell receptor.
In 1986, he joined the faculty as an assistant professor at Columbia University, started an independent research laboratory, focusing on gene transcription, and was Associate Clinical Professor of Medicine when he left to join Merck.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PRIME MEDICINE, INC.
3,63% | 25/02/2024 | 4 348 578 ( 3,63% ) | 30 M $ | 31/03/2024 |
Postes actifs de Keith Gottesdiener
| Sociétés | Poste | Début |
|---|---|---|
| PRIME MEDICINE, INC. | Chief Executive Officer | 01/07/2020 |
Cardurion Pharmaceuticals LLC
 Cardurion Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA. | Director/Board Member | - |
Excellentia Global Partners
 Excellentia Global Partners Financial ConglomeratesFinance Excellentia Global Partners is a life sciences investment bank that works with life science companies, medical device, diagnostic/proteomics companies. The private company is based in New York, NY. The company connects its life science clients with sources of capital in the venture capital and private equity arena. The CEO of the company is Keith M. Gottesdiener. | Chief Executive Officer | - |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | - |
Anciens postes connus de Keith Gottesdiener
| Sociétés | Poste | Fin |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Director/Board Member | 08/11/2023 |
| RHYTHM PHARMACEUTICALS, INC. | Chief Executive Officer | 28/03/2020 |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Corporate Officer/Principal | 01/10/2011 |
| Columbia University College of Physicians & Surgeons | Corporate Officer/Principal | 01/01/2004 |
| The Trustees of Columbia University in The City of New York | Corporate Officer/Principal | 01/01/1995 |
Formation de Keith Gottesdiener
| University of Pennsylvania | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| PRIME MEDICINE, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
Allergan GI Corp.
 Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |
Excellentia Global Partners
Excellentia Global Partners Financial ConglomeratesFinance Excellentia Global Partners is a life sciences investment bank that works with life science companies, medical device, diagnostic/proteomics companies. The private company is based in New York, NY. The company connects its life science clients with sources of capital in the venture capital and private equity arena. The CEO of the company is Keith M. Gottesdiener. | Finance |
Cardurion Pharmaceuticals LLC
Cardurion Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA. | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
